ResMed (RMD) PT Raised to $255 at RBC Capital, Citing 'Robust Growth And Tariff Exemptions'
Tweet Send to a Friend
RBC Capital analyst Craig Wong-Pan raised the price target on ResMed (NYSE: RMD) to $255.00 (from $247.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
